Market Overview

Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019

Share:

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to
bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of people living with
chronic skin conditions, will report financial results for the quarter
ended March 31, 2019 and provide an operational update after market
close on Tuesday, May 7, 2019. The company will host a conference call
and an audio webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)
on the same day.

     

Conference Call Information:

Domestic callers: 1-877-359-9508
International callers: 1-224-357-2393
Passcode: 3485374
 

Webcast information: Visit http://investors.dermira.com.

A webcast replay will be available on the Dermira website for 30 days.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech
ingenuity to medical dermatology by delivering differentiated, new
therapies to the millions of patients living with chronic skin
conditions. Dermira is committed to understanding the needs of both
patients and physicians and using its insight to identify, develop and
commercialize leading-edge medical dermatology products. The company's
approved treatment, QBREXZA™ (glycopyrronium) cloth, is indicated for
pediatric and adult patients (ages 9 and older) with primary axillary
hyperhidrosis (excessive underarm sweating). Please see the QBREXZA prescribing
information
. Dermira is evaluating lebrikizumab for the treatment of
moderate-to-severe atopic dermatitis (a severe form of eczema) and plans
to initiate a Phase 3 clinical development program by the end of 2019,
subject to an end-of-Phase 2 meeting with the U.S. Food and Drug
Administration. Dermira also has early-stage research and development
programs in other areas of dermatology. Dermira is headquartered
in Menlo Park, Calif. For more information, please visit http://www.dermira.com.
Follow Dermira on Twitter,
LinkedIn
and Instagram.

In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc-),
corporate Instagram account (https://www.instagram.com/dermira_inc/)
and corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned financial
and other announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed material
information and Dermira may use these channels to comply with its
disclosure obligations under Regulation FD. Therefore, investors should
monitor Dermira's website, LinkedIn page, Instagram and Twitter accounts
in addition to following its SEC filings, news releases, public
conference calls and webcasts.

Forward-Looking Statements

The information in this news release contains forward-looking statements
and information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to the "safe harbor" created by
those sections. This news release contains forward-looking statements
that involve substantial risks and uncertainties, including statements
with respect to Dermira's goal of bringing biotech ingenuity to medical
dermatology by delivering differentiated, new therapies to the millions
of patients living with chronic skin conditions and Dermira's plans to
initiate a Phase 3 development program for lebrikizumab by the end of
2019, subject to an end-of-Phase 2 meeting with the U.S. Food and Drug
Administration. These statements deal with future events and involve
known and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially different
from the information expressed or implied by these forward-looking
statements. Factors that could cause actual results to differ materially
include risks and uncertainties such as those relating to Dermira's
dependence on third-party clinical research organizations,
manufacturers, suppliers and distributors; the design and implementation
of Dermira's clinical trials; the outcomes of future meetings with
regulatory agencies; Dermira's ability to attract and retain key
employees; Dermira's ability to manage the growth and complexity of its
organization; Dermira's ability to maintain, protect and enhance its
intellectual property; and Dermira's ability to continue to stay in
compliance with its material contractual obligations, applicable laws
and regulations. You should refer to the section entitled "Risk Factors"
set forth in Dermira's Annual Report on Form 10-K, Dermira's Quarterly
Reports on Form 10-Q and other filings Dermira makes with the SEC from
time to time for a discussion of important factors that may cause actual
results to differ materially from those expressed or implied by
Dermira's forward-looking statements. Furthermore, such forward-looking
statements speak only as of the date of this news
release. Dermira undertakes no obligation to publicly update any
forward-looking statements or reasons why actual results might differ,
whether as a result of new information, future events or otherwise,
except as required by law.

View Comments and Join the Discussion!